The Prevalence and Risk Factors for at‐Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care

Documenti analoghi

• Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
  di: C. C. Mark Cheah, et al.
  Pubblicazione: (2025)
• Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
  di: Xiao‐Dong Zhou, et al.
  Pubblicazione: (2025)
• Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
  di: Kaleb Tesfai, et al.
  Pubblicazione: (2026)
• Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
  di: Shinya Yokoyama, et al.
  Pubblicazione: (2025)
• Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes
  di: Na Tian, et al.
  Pubblicazione: (2025)